The New Belkin UltraCharge Collection Brings Fast, Stylish Power at 25W
22.8.2025 16:00:00 EEST | Business Wire | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced three new Qi2 25W certified wireless charging solutions, expanding its award-winning mobile power portfolio. These new products harness the power of the latest Qi2 standard, delivering up to 25W wireless charging with enhanced efficiency, thermal management, and cross-device compatibility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250822916646/en/
Belkin UltraCharge 25W Collection
The announcement follows Belkin’s successful certification of multiple products under the new Qi2 25W protocol, setting the stage for high-performance, future-ready accessories that meet the evolving needs of consumers and devices alike.
All three UltraCharge products are thoughtfully engineered with Belkin’s hallmark focus on safety, performance, and design. Supporting up to 25W wireless charging, the UltraCharge collection delivers charging speeds up to 5X faster1 than standard Qi chargers. Each product features Belkin’s proprietary new ChillBoost™ cooling technology, which actively regulates device temperatures for safe, high-speed charging. They also undergo Belkin’s rigorous SmartProtect testing which includes extensive quality control processes to assure safety and reliability. The UltraCharge collection is made with 85% recycled plastic, and packaging is 100% plastic-free, aligning with Belkin’s ongoing efforts to reduce waste and build products more responsibly.
The World's First Qi2 25W Certified Collection
UltraCharge Pro 3-in-1 Magnetic Charging Dock
The fastest and most advanced in the UltraCharge lineup, the UltraCharge Pro is designed for those who value performance and polish. Whether placed on a bedside table, desk, or countertop, UltraCharge Pro elevates any space while keeping your devices powered, protected, and ready to go.
Key features:
- Charges iPhone from 0–50% in just 25 minutes2 and Apple Watch from 0–80% in 30 minutes3
- Charges three devices at once: iPhone, Apple Watch, and AirPods
- Adjustable viewing angle up to 70° in portrait or landscape
- Weighted base with magnetic snap-on for easy one-handed placement
- Premium materials including chrome finish and soft-touch silicone base
- Includes 45W USB-C power adapter and 5-ft./1.5m USB-C to USB-C cable
UltraCharge 3-in-1 Foldable Magnetic Charger
Designed with portability in mind, the UltraCharge 3-in-1 features a foldable, lightweight form factor perfect for travel, while powering up to three devices at once. Ideal for busy professionals, frequent travelers, and design-conscious users who rely on a streamlined daily tech setup, UltraCharge 3-in-1 combines performance, flexibility, and ease of use.
Key features:
- Charges iPhone from 0–50% in just 29 minutes4
- Foldable, lightweight design for travel-friendly portability
- Powers up to three devices at once: iPhone, Apple Watch, and AirPods
- Adjustable viewing angle in portrait or landscape
- Includes 45W USB-C power adapter and 5-ft./1.5m USB-C to USB-C cable
UltraCharge 2-in-1 Foldable Magnetic Charger
The UltraCharge 2-in-1 delivers ultra-fast wireless charging, plus a bonus USB-C port for an optional third device such as a smartwatch. It’s perfect for those who want maximum speed without the bulk. From home setups to carry-on bags, this charger is built for life on the go.
Key features:
- Simultaneously charges 2 devices wirelessly, with bonus USB-C port for third device (5W)
- Foldable, lightweight form factor designed for travel
- Compatible with both Apple and Android devices
- Converts from pad to stand with adjustable viewing angle
- Includes 45W USB-C power adapter and 5-ft./1.5m USB-C to USB-C cable
Unlocking Qi2 25W: Why It Matters
Qi2 25W is the latest evolution of the Qi wireless charging standard, developed by the Wireless Power Consortium. It delivers faster charging speeds (up to 25W), greater energy efficiency, and improved compatibility across a wider range of devices and brands. This next-gen standard paves the way for a new era of wireless accessories that offer higher power without the need for cables. Belkin’s new Qi2 25W certified products are built to meet these demands, offering future-ready performance for the latest smartphones capable of supporting faster wireless charging.
Availability
- UltraCharge Pro 3-in-1 is available to order now on belkin.com, amazon.com, AT&T and select retailers worldwide for $129.99 USD MSRP.
- UltraCharge 3-in-1 is available to order now on belkin.com, amazon.com, AT&T and select retailers worldwide for $99.99 USD MSRP.
- UltraCharge 2-in-1 is available to order now on belkin.com, amazon.com and select retailers worldwide for $59.99 USD MSRP.
Media kit can be found HERE.
1 Based on internal testing, charging delivers up to 25W of power, compared to a 5W Qi charger. Actual results will vary.
2 Based on internal testing. Belkin Qi2 25W wireless technology charges iPhone 16 from 0-50% in 25 minutes using iOS 26 or newer. Charge time varies with environmental factors; actual results will vary.
3 Based on internal testing. Actual results will vary.
4 Based on internal testing. Actual results will vary.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250822916646/en/
Contacts
Media Contact
Jen Wei
VP of Global Communications and Digital Marketing
comms@belkin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom